Objective. To describe drug utilization and cost in a large hospital and to compare the impact of different strategies on cost associated with drug prescribing.
Discussion. Our study suggests that reducing inappropriate use of high volume drugs such as antibiotics could be more effective in optimising health facility drug budgets than attempts concentrating solely on reducing use of high cost drugs alone. Moreover our study suggests that systematic measurement of drug utilisation patterns is a key element of drug cost control strategies.
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Outside of salaries and wages, pharmaceuticals represents drugs) and patient factors (such as severity of illness and number of co-morbidities) are not amenable to change, but one of the highest costs to acute hospitals. In Australia, a large hospital may have a pharmaceuticals budget of $10-20 hospital control mechanisms and the prescribing patterns of clinicians may be changed. million per annum, yet it is common for hospitals to spend significantly in excess of this budget. This was the case in Cost control can be achieved by targeting either high cost drugs (which are usually low in volume); or high volume, the study hospital, despite significant efforts to contain costs. These efforts included procurement of pharmaceuticals at low-moderate cost drugs (such as antibiotics and anticoagulants). The former is the most commonly utilized costminimum costs, contracting with external consultants to advise on drug costs and consideration of a scheme where containment strategy in hospitals [1, 2] , usually taking the form of monitoring and restricting the use of S-100 drugs patients bring their own medications into hospital. The mainstay of efforts to contain costs at this hospital was and other expensive drugs. S-100 drugs are highly specialized, expensive drugs, which can only be prescribed by specialized monitoring and restriction of the use of expensive drugs.
The four major determinants of the cost of pharmaceuticals hospital units and dispensed through pharmacies associated with hospitals that participate in the 'Highly Specialized Drugs to hospitals are summarized in Figure 1 . These are market factors, patient factors, hospital control mechanisms and Program'. Examples include expensive drugs for the treatment of AIDS or bone marrow transplants. The government prescribing practice. Market factors (such as the cost of acute beds and serves a population of 1.5 million people. Retrospective data on drug utilization and cost, linked to patient clinical data and prescriber data were extracted from a series of linked, relational hospital health databases for the month of November 1998. These databases contain data on every patient episode of care, including patient demographics, administrative details, ward, bed days, diagnoses, procedures, pharmaceuticals and clinical costing data. An episode of care is defined as a single stay in hospital, beginning with admission and ending with discharge, death or transfer. The costs analysed were for all pharmaceuticals administered during the hospital stay, in all sites (wards, operating theatre, and emergency). The administrative and costing data were highly reliable, as they were obtained directly from patient activity while in hospital. Only direct costs to the hospital of phar- Figure 1 Factors influencing the cost of pharmaceuticals to maceuticals were included in the analysis. Indirect costs such hospitals.
as the costs of administering drugs or the cost of restricting drugs were not included. The quality of clinical information, reimburses hospitals for S-100 drugs only if they are prehowever, depends on the coding of medical record data into scribed for listed (approved) indications. If the drugs are International Classification of Disease version 9 (ICD-9-used in hospitals for other indications, the hospital bears the CM) codes [22] . Studies have shown that coding of clinical full cost of the drug. These drugs are usually the focus of information is reasonably accurate in Australia [23] . Analysis attention in hospitals because they are individually expensive.
of a full years data showed that November is a representative In contrast, not much attention is paid to commonly used, month in terms of number of separations and pharmacy high volume drugs such as antibiotics and anticoagulants, which expenditure. are used across all specialties. As more physicians prescribe Predictors of cost examined were patient demographics, these high volume drugs, variation in prescribing practice and S-100 status, clinical unit, type of drugs, inpatient or outpatient deviation from guidelines is more likely [3] [4] [5] . A survey of 10 status, intensive care unit (ICU) admission, emergency adoverseas hospitals found that antibiotics, intravenous fluids mission, length of stay and death. Clinical diagnoses were and tranquilisers were the most commonly prescribed, and that analyzed by Major Diagnostic Category (MDC) [22] . there were significant, unpredictable variations in prescribing practices [6] . A study of drug costs in a surgical intensive care
Data analysis unit found that 70% of drug costs were attributed to antibiotics and blood products [7] . At an Australian hospital, review of Descriptive statistics, which included mean, median and antibiotic prescribing found significant potential for cost saving proportion, were used to describe continuous and categorical by targeting inappropriate prescribing habits [3] .
variables. Multiple logistic regression, using SAS [24] , was Despite clear, evidence-based clinical practice guidelines in used to identify predictors for drug costs per episode. In the most areas of medicine, it has been shown that clinical logistic regression model, the outcome variable was cost. A practice (including drug prescribing) can vary significantly dichotomous variable based on the 75 th percentile as a cutbetween practitioners, to a degree that cannot be explained by off point, was created. High cost was therefore defined as independent patient factors [8] [9] [10] . Physician non-compliance cost > 75 th percentile. Dichotomous predictor variables were with guidelines can partially explain this variation [11] [12] [13] [14] .
created for S-100 status, medical units, antibiotics, antiThe cost, safety and effectiveness of drugs used in clinical coagulants, anti-ulcer drugs and outpatient status. Only antipractice depends on the systematic practice of evidence based biotics used for bacterial infections were included in the medicine. Failure to use evidence-based prescribing can result variable 'antibiotics'. Patient age, sex and use of antivirals in ad-hoc practices, sub-optimal patient outcomes, adverse were examined as predictor variables, but did not add anything drug reactions and poor use of resources [15] [16] [17] [18] [19] [20] . Adverse to the model. drug events themselves have been shown to result in sigCost modeling was performed using Microsoft Excel [25] nificant, avoidable costs [21] .
and examined the impact of varying reductions in use of The aim of this study was therefore to determine the different groups of drugs. The groups of drugs included in pattern of drug utilization and cost in a large teaching hospital the model were chosen because of the high volume of use. and to compare the impact of different strategies on cost The data collected for one month were projected to estimate associated with drug prescribing at a large hospital in Sydney. costs for a complete year.
Methods Results
We conducted a cross sectional study with cost modelling at There were 25 313 inpatient and outpatient episodes of care recorded in the health database for November 1998. The a large hospital in Sydney, Australia. This hospital has 690 total) , so that the total cost of S-100 drugs was only Anticoagulants 125 76-212 3.7% of the total cost of pharmaceuticals to the hospital for Anti-ulcer 2.25 2-2.5 the month. The largest proportional cost for a single drug Outpatient 0.27 0.24-0.31 category was for antibiotics, which accounted for nearly 14% of total drug costs, followed by anti-ulcer drugs, which accounted for 7% of total drug costs. The majority of drug costs (79%) were incurred by medical units, followed by most commonly prescribed drugs and S-100 drugs were prescribed. It shows that the use of S-100 drugs is extremely surgical units (14%). Inpatient use of drugs accounted for 91% of costs, compared to only 9% in outpatient use. low. Figure 3 shows the contribution of the most commonly prescribed drugs and S-100 drugs to the proportion of total Oncology accounted for 42% of the total drug costs. Table 2 shows a logistic regression model for predictors drug costs. Despite the cost of S-100 drugs being expensive per episode, the total cost to the hospital is relatively low. of high cost per episode of care. The strongest predictor of cost per episode of care was S-100 drugs, followed by Table 3 shows a model which compares the savings which could be made following a 20% reduction in the use of anticoagulants and antibiotics. Figure 2 shows the proportion of episodes in which the various drug types. The largest impact is made by a reduction range of clinical settings and for many different conditions. In the latter scenario, the use of the drug spans many disciplines and wards, which often have different practices and policies and is therefore subject to much greater variation in clinical practice. It makes empiric sense that a policy restricting the use of indinavir will be less effective than one which restricts the use of cefotaxime. The high costs in cardiology are contributed to by use of thrombolytic therapy (TT) for myocardial infarction. We did not focus on TT for the same reason. There is a strict TT protocol in the hospital, with rigid eligibility criteria for TT. The only TT agent used Figure 2 Frequency of prescription of commonly prescribed in the hospital is streptokinase, and therefore we did not feel drugs and S-100 drugs.
there was any gain in pursuing TT as a means of reducing drug costs. The same rationale applies to excluding oncology drugs. Any strategy to contain costs must, therefore, focus on areas where change can realistically be achieved -that is, on arms B and C in Figure 1 . Unfortunately, current strategies do focus on limiting the use of expensive S-100 drugs, which are reflected more in arm D of Figure 1 .
Our study shows that S-100 drugs, whilst individually expensive, are not used frequently, so that the impact of reducing their use on overall costs is minimal. A much greater impact on cost is achieved by reducing the use of high volume drugs, particularly antibiotics, which are the single most commonly prescribed category of drugs in hospital [3] . In addition, because S-100 drugs are used in such defined, specialized settings, there is less likelihood of inappropriate Figure 3 Contribution of the most commonly prescribed variation in prescribing practice. This means that our estimate drugs and S-100 drugs to the proportion of total drug costs.
of 20% reduction in use for S-100 drugs is unlikely to be achieved in practice, so that the real cost savings are even in antibiotic use, resulting in four times the savings made by less. A 5-10% reduction in use may realistically be achieved. a similar reduction in the use of S-100 drugs. If the use of It is much more likely that there are significant in-S-100 drugs was reduced by just 5-10%, the annual saving appropriate variations in prescribing practice for antibiotics, would only be $15 348-$30 696.
which are prescribed broadly across a hospital, in all specialties and by all levels of clinicians. Due to higher variation, a 20% reduction in usage of antibiotics may be more achievable in practice, so that the true cost savings may be up to 16 times Discussion that achieved by reducing S-100 drugs by 5%. An area of antibiotic and anticoagulant use which may be Our data show that the greatest pharmaceutical costs in subject to clinical practice variation is the use of oral versus hospital are incurred by inpatients, particularly medical intravenous (in the case of antibiotics) or subcutaneous versus patients. We showed that over 40% of costs are incurred by intravenous (in the case of anticoagulants) therapy. We were oncology patients. Cardiology (circulatory system) was also a unable to study this, but this is an important area for high cost area. However, it is less likely that there is a high consideration in reducing drug costs. In one Australian hosdegree of variation in prescribing practice in specialized pital, antibiotics were the most commonly prescribed drugs, settings such as oncology or cardiology. The need for speand were prescribed to 42% of inpatients. Of these, 65% cialized, expensive drugs such as those used in oncology, were prescribed parenterally and 35% orally, with a total cardioliogy or HIV medicine are influenced more by patient number of doses estimated at 200 200 per year at a total cost clinical factors (arm D in Figure 1 ) than prescribing habits, of nearly 2 million dollars for this hospital alone [3] . Antibiotic and are less amenable to change. A simple illustration is the use exceeded that of the other most commonly prescribed use of indinavir, a protease inhibitor used for the treatment drugs in hospitals, anticoagulants and anti-ulcer drugs [4, 5] . of AIDS, versus the use of cefotaxime, and antibiotic used Whilst it is tempting to focus on high cost, low volume for a wide range of indications. Indinavir is an S-100 drug, drugs, gains are more readily achieved by focussing on high and is only used for the treatment of AIDS patients, and in volume drugs, such as antibiotics, anticoagulants and antian Australian hospital can only be prescribed by HIV physulcer drugs. The use of such drugs span all disciplines, and icians. In contrast, cefotaxime is used by a wide array of they are used by a much wider range of clinicians, so that internal medicine specialists, including surgeons, gynaecologists, general physicians and junior residents in a wide there is more room for variation in prescribing practice. Due to these factors and the high volume of usage, strategies drug-related adverse events and hospital length of stay [15] . which target inappropriate use of these drugs are more likely These examples show that costs associated with hospital to make an impact on cost. We also found that antivirals pharmaceuticals can be reduced. were expensive and contributed significantly to the total The problem of reducing inappropriate prescribing is a pharmaceutical costs, but these are not generally used across challenge, but one which has been successfully tackled in all disciplines. some instances. Drug utilization review is a necessary step The majority of successful strategies to reduce drug cost towards changing prescribing practice, and systematically have focussed on changing drug utilization and prescribing addressing, understanding and reducing drug costs [49, 50] . habits [26, 27] . Hospital control mechanisms, on the other The systematic collection and analysis of drug utilization data hand, have less potential to impact on cost saving, because has been proven to reduce costs [51] . The Australasian they are limited by patient factors (such as type and severity Society of Clinical and Experimental Pharmacologists and of illness), which are not amenable to change. Restriction of Toxicologists, and the Drug Usage Evaluation Network of the use of more expensive aminoglycosides in a US hospital Australia have outlined a strategy for drug utilization evaluresulted in only modest cost savings [2] . A New Zealand ation (DUE), which many hospitals have already implemented study showed that the combination of a preferred drug list [52] . A New Zealand hospital reported significant cost con-(procedural change) and a drug utilization review (clinical tainment after introducing DUE and a 'preferred drug' list practice change) reduced drug costs, but the relative con-to encourage doctors to adhere to prescribing guidelines [28] . tribution of each change could not be determined [28] .
Our study suggests that reducing inappropriate use of high Variation in practice has been addressed by a number of volume drugs such as antibiotics can be more effective studies which show that evidence-based decision support sys-in optimizing health facility drug budgets than attempts tems result in more cost-effective delivery of health care [29-concentrating solely on reducing use of high cost drugs alone. 35] . A study in the United Kingdom (UK) found that left to Moreover, our study suggests that systematic measurement their own devices, doctors ignored a cheaper, equally effective of drug utilization patterns is a key element of drug cost drug in a median 50% (range 25-75%) of cases. Where they control strategies. Without a systematic understanding of the were encouraged with clinical decision support, this figure de-patterns of drug usage and areas of major variation from creased to 36% (8-67%) with limited support and 35% (0-67%) recommended guidelines for drug use, attempts at controlling with full support [30] . Another study found that use of a com-drug costs will be undirected. puterized decision support system significantly reduced the Our recommendation, therefore, is that all health facilities time to achieving stable, therapeutic levels of anticoagulation implement a systematic drug usage evaluation mechanism to in patients, and resulted in better quality of care when used by identify high use drugs and potential for improvement. In a nurse-practitioner compared to that by trainee doctors who addition clinicians, pharmacists and managers need to work were not using such a system [35] .
together to determine strategies to reduce inappropriate preThe use of computerized decision support systems in scribing. These strategies, which will increasingly involve the clinical practice has been described in a wide range of settings, use of interactive computerized decision support systems, ranging from outpatient clinics to intensive care units [36] [37] [38] [39] [40] [41] [42] [43] [44] . will require continuing education, regular dissemination of In the UK and Holland, computerized systems to assist prescribing guidelines and drug utilization evaluation ingeneral practitioners in prescribing have been developed. The formation and feedback. It is also important to recognise Prodigy system in the UK provides computerized advice on that pharmacy budget is only one aspect of cost, and that different drug choices to general practitioners during the the impact of total treatment costs, including indirect costs, consultation, and has been tested on a national basis and should be considered. shown to be effective [45, 46] . It is proposed that this be developed into a national system for everyday use by general practitioners [46] .
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